Log In
BCIQ
Print this Print this
 

Biosimilar infliximab (GS071)

  Manage Alerts
Collapse Summary General Information
Company Aprogen Inc.
DescriptionBiosimilar of infliximab, a chimeric mAb against tumor necrosis factor (TNF) alpha
Molecular Target Tumor necrosis factor (TNF) alpha
Mechanism of ActionTumor necrosis factor (TNF) alpha inhibitor; Antibody; Biosimilar
Therapeutic ModalityBiologic: Antibody-drug conjugate
Latest Stage of DevelopmentRegistration
Standard IndicationRheumatoid arthritis (RA)
Indication DetailsTreat rheumatoid arthritis (RA)
Regulatory Designation
PartnerNichi-Iko Pharmaceutical Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today